Sarepta Therapeutics has announced a significant regulatory milestone in its efforts to secure permanent FDA approval for two breakthrough Duchenne muscular dystrophy (DMD) treatments. As reported by BusinesWire.com, the company received positive feedback from the FDA regarding its plan to submit supplemental new drug applications (sNDAs) by the end of April 2026, seeking conversion of AMONDYS 45® (casimersen) and VYONDYS 53® (golodirsen) from accelerated to traditional approval status.
A Path Forward for Rare Disease Treatment
Both medications were approved through the FDA’s accelerated approval pathway, a regulatory mechanism designed to expedite access to treatments for serious conditions. Now, Sarepta is leveraging comprehensive clinical and real-world evidence to support full approval. The FDA has confirmed that the company can submit data from the ESSENCE confirmatory study alongside substantial real-world evidence accumulated over more than a decade of use in over 1,800 patients worldwide.
“This regulatory approach recognizes the unique challenges of studying rare genetic diseases,” explained Louise Rodino-Klapac, Sarepta’s President of Research & Development. She emphasized that meaningful functional changes in DMD unfold over years rather than months, making real-world data particularly valuable for understanding long-term therapeutic outcomes in ultra-rare patient populations.
Clinical Evidence and Study Results
The ESSENCE study, a Phase 3 randomized, double-blind, placebo-controlled trial, enrolled 225 patients ages 6-13 years with DMD amenable to exon 45 or 53 skipping. While topline results showed numerical trends favoring treatment over placebo, the primary endpoint, 4-step ascend velocity at 96 weeks, did not achieve statistical significance (P=0.309), with a difference of 0.06 steps per second.
However, an updated analysis excluding approximately 10% of participants whose baseline measurements occurred during the COVID-19 pandemic revealed more promising findings: a difference of 0.12 steps per second (P=0.050), suggesting potential clinical benefit when pandemic-related variables are removed.
Real-World Evidence Demonstrates Substantial Benefits
Beyond clinical trials, extensive real-world data supports the therapeutic value of these exon-skipping therapies. Patients treated with VYONDYS 53 experienced a 7.5-year delay in requiring nighttime ventilation, while AMONDYS 45 treatment showed statistically significant slowing of lung function decline. Across the broader PMO (phosphorodiamidate morpholino oligomer) portfolio, real-world evidence indicates multi-year survival benefits, 3–4-year delays in losing ambulation, substantial reduction in cardiac complications, and significantly fewer emergency room visits.
Safety Profile Remains Favorable
The ESSENCE study reinforced the favorable safety profiles of both therapies. Adverse events were predominantly mild (88%) or moderate (10.9%), with no new safety signals detected. This consistency aligns with the stable safety record observed over more than a decade of clinical use.
Looking Ahead
By submitting sNDAs by April’s end, Sarepta aims to demonstrate that accumulated clinical and real-world evidence sufficiently supports permanent FDA approval. This regulatory strategy acknowledges the complexity of developing therapies for genetically defined patient populations and represents an important evolution in how rare disease treatments can achieve full approval status. The outcome could establish a meaningful precedent for other precision genetic medicines currently under development.
